|
1
|
Todisco A: Regulation of gastric
metaplasia, dysplasia, and neoplasia by bone morphogenetic protein
signaling. Cell Mol Gastroenterol Hepatol. 3:339–347. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nitsche H, Ramamoorthy S, Sareban M,
Pausawasdi N and Todisco A: Functional role of bone morphogenetic
protein-4 in isolated canine parietal cells. Am J Physiol
Gastrointest Liver Physiol. 293:G607–G614. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maloum F, Allaire JM, Gagné-Sansfaçon J,
Roy E, Belleville K, Sarret P, Morisset J, Carrier JC, Mishina Y,
Kaestner KH, et al: Epithelial BMP signaling is required for proper
specification of epithelial cell lineages and gastric endocrine
cells. Am J Physiol Gastrointest Liver Physiol. 300:G1065–G1079.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wen XZ, Akiyama Y, Baylin SB and Yuasa Y:
Frequent epigenetic silencing of the bone morphogenetic protein 2
gene through methylation in gastric carcinomas. Oncogene.
25:2666–2673. 2006. View Article : Google Scholar
|
|
5
|
Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim SG, Park HR, Min SK, Choi JY, Koh SH,
Kim JW and Lee HW: Expression of bone morphogenic protein-4 is
inversely related to prevalence of lymph node metastasis in gastric
adenocarcinoma. Surg Today. 41:688–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL,
Kim JS and Yoo YA: Metastatic function of BMP-2 in gastric cancer
cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9
expression. Exp Cell Res. 317:1746–1762. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tarragona M, Pavlovic M, Arnal-Estapé A,
Urosevic J, Morales M, Guiu M, Planet E, González-Suárez E and
Gomis RR: Identification of NOG as a specific breast cancer bone
metastasis-supporting gene. J Biol Chem. 287:21346–21355. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Virk MS, Petrigliano FA, Liu NQ,
Chatziioannou AF, Stout D, Kang CO, Dougall WC and Lieberman JR:
Influence of simultaneous targeting of the bone morphogenetic
protein pathway and RANK/RANKL axis in osteolytic prostate cancer
lesion in bone. Bone. 44:160–167. 2009. View Article : Google Scholar
|
|
10
|
Laurila R, Parkkila S, Isola J,
Kallioniemi A and Alarmo EL: The expression patterns of gremlin 1
and noggin in normal adult and tumor tissues. Int J Clin Exp
Pathol. 6:1400–1408. 2013.PubMed/NCBI
|
|
11
|
Szász AM, Lánczky A, Nagy Á, Förster S,
Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B:
Cross-validation of survival associated biomarkers in gastric
cancer using transcriptomic data of 1,065 patients. Oncotarget.
7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vasaikar SV, Straub P, Wang J and Zhang B:
LinkedOmics: Analyzing multiomics data within and across 32 cancer
types. Nucleic Acids Res. 46(D1): D956–D963. 2018. View Article : Google Scholar
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
14
|
Guo X and Wang XF: Signaling cross-talk
between TGF-beta/BMP and other pathways. Cell Res. 19:71–88. 2009.
View Article : Google Scholar
|
|
15
|
da Cunha Santos G, Shepherd FA and Tsao
MS: EGFR mutations and lung cancer. Annu Rev Pathol. 6:49–69. 2011.
View Article : Google Scholar
|
|
16
|
Khan SA, Zeng Z, Shia J and Paty PB: EGFR
gene amplification and KRAS mutation predict response to
combination targeted therapy in metastatic colorectal cancer.
Pathol Oncol Res. 23:673–677. 2017. View Article : Google Scholar :
|
|
17
|
Troiani T, Martinelli E, Capasso A,
Morgillo F, Orditura M, De Vita F and Ciardiello F: Targeting EGFR
in pancreatic cancer treatment. Curr Drug Targets. 13:802–810.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao L, He LR, Xi M, Cai MY, Shen JX, Li
QQ, Liao YJ, Qian D, Feng ZZ, Zeng YX, et al: Nimotuzumab promotes
radiosensitivity of EGFR-overexpression esophageal squamous cell
carcinoma cells by upregulating IGFBP-3. J Transl Med. 10:2492012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weng X, Zhang H, Ye J, Kan M, Liu F, Wang
T, Deng J, Tan Y, He L and Liu Y: Hypermethylated Epidermal growth
factor receptor (EGFR) promoter is associated with gastric cancer.
Sci Rep. 5:101542015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nam HJ, Ching KA, Kan J, Kim HP, Han SW,
Im SA, Kim TY, Christensen JG, Oh DY and Bang YJ: Evaluation of the
antitumor effects and mechanisms of PF00299804, a pan-HER
inhibitor, alone or in combination with chemotherapy or targeted
agents in gastric cancer. Mol Cancer Ther. 11:439–451. 2012.
View Article : Google Scholar
|
|
21
|
Zhang J, He XC, Tong WG, Johnson T,
Wiedemann LM, Mishina Y, Feng JQ and Li L: Bone morphogenetic
protein signaling inhibits hair follicle anagen induction by
restricting epithelial stem/progenitor cell activation and
expansion. Stem Cells. 24:2826–2839. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang L, Meng F, Ma D, Xie W and Fang M:
Bridging Decapentaplegic and wingless signaling in Drosophila wings
through repression of naked cuticle by Brinker. Development.
140:413–422. 2013. View Article : Google Scholar
|
|
23
|
Lu Z, Ghosh S, Wang Z and Hunter T:
Downregulation of caveolin-1 function by EGF leads to the loss of
E-cadherin, increased transcriptional activity of beta-catenin, and
enhanced tumor cell invasion. Cancer Cell. 4:499–515. 2003.
View Article : Google Scholar
|
|
24
|
Ji H, Wang J, Nika H, Hawke D, Keezer S,
Ge Q, Fang B, Fang X, Fang D, Litchfield DW, et al: EGF-induced ERK
activation promotes CK2-mediated disassociation of alpha-Catenin
from beta-Catenin and transactivation of beta-Catenin. Mol Cell.
36:547–559. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Klose A, Waerzeggers Y, Monfared P,
Vukicevic S, Kaijzel EL, Winkeler A, Wickenhauser C, Löwik CW and
Jacobs AH: Imaging bone morphogenetic protein 7 induced cell cycle
arrest in experimental gliomas. Neoplasia. 13:276–285. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Terashima M, Kitada K, Ochiai A, Ichikawa
W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H and Sasako
M; ACTS-GC Group: Impact of expression of human epidermal growth
factor receptors EGFR and ERBB2 on survival in stage II/III gastric
cancer. Clin Cancer Res. 18:5992–6000. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK
and Kim WH: EGFR in gastric carcinomas: Prognostic significance of
protein overexpression and high gene copy number. Histopathology.
52:738–746. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Petrini I, Lencioni M, Vasile E, Fornaro
L, Belluomini L, Pasquini G, Ginocchi L, Caparello C, Musettini G,
Vivaldi C, et al: EGFR and AKT1 overexpression are mutually
exclusive and associated with a poor survival in resected gastric
adenocarcinomas. Cancer Biomark. 21:731–741. 2018. View Article : Google Scholar
|
|
29
|
Moutinho C, Mateus AR, Milanezi F,
Carneiro F, Seruca R and Suriano G: Epidermal growth factor
receptor structural alterations in gastric cancer. BMC Cancer.
8:102008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang KL, Wu TT, Choi IS, Wang H, Resetkova
E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, et al:
Expression of epidermal growth factor receptor in esophageal and
esophagogastric junction adenocarcinomas: Association with poor
outcome. Cancer. 109:658–667. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gkolfinopoulos S, Papamichael D,
Papadimitriou K, Papanastasopoulos P, Vassiliou V and Kountourakis
P: Advances in molecular, genetic and immune signatures of gastric
cancer: Are we ready to apply them in our patients' decision
making? World J Gastrointest Oncol. 10:172–183. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shinohara M, Mao M, Keeley TM, El-Zaatari
M, Lee HJ, Eaton KA, Samuelson LC, Merchant JL, Goldenring JR and
Todisco A: Bone morphogenetic protein signaling regulates gastric
epithelial cell development and proliferation in mice.
Gastroenterology. 139:2050–2060. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jin X, Yin J, Kim SH, Sohn YW, Beck S, Lim
YC, Nam DH, Choi YJ and Kim H: EGFR-AKT-Smad signaling promotes
formation of glioma stem-like cells and tumor angiogenesis by
ID3-driven cytokine induction. Cancer Res. 71:7125–7134. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sapkota G, Alarcón C, Spagnoli FM,
Brivanlou AH and Massagué J: Balancing BMP signaling through
integrated inputs into the Smad1 linker. Mol Cell. 25:441–454.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Scholze AR, Foo LC, Mulinyawe S and Barres
BA: BMP signaling in astrocytes downregulates EGFR to modulate
survival and maturation. PLoS One. 9:e1106682014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jamora C, DasGupta R, Kocieniewski P and
Fuchs E: Links between signal transduction, transcription and
adhesion in epithelial bud development. Nature. 422:317–322. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wainberg ZA, Lin LS, DiCarlo B, Dao KM,
Patel R, Park DJ, Wang HJ, Elashoff R, Ryba N and Hecht JR: Phase
II trial of modified FOLFOX6 and erlotinib in patients with
metastatic or advanced adenocarcinoma of the oesophagus and
gastro-oesophageal junction. Br J Cancer. 105:760–765. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lordick F, Luber B, Lorenzen S,
Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E,
Röthling N, Schuster T, et al: Cetuximab plus
oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic
gastric cancer: A phase II study of the Arbeitsgemeinschaft
Internistische Onkologie (AIO). Br J Cancer. 102:500–505. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lordick F, Kang YK, Chung HC, Salman P, Oh
SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et
al Arbeitsgemeinschaft Internistische Onkologie and EXPAND
Investigators: Capecitabine and cisplatin with or without cetuximab
for patients with previously untreated advanced gastric cancer
(EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol.
14:490–499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Waddell T, Chau I, Cunningham D, Gonzalez
D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G,
Wadsley J, et al: Epirubicin, oxaliplatin, and capecitabine with or
without panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): A randomised, open-label phase 3
trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ye L, Kynaston H and Jiang WG: Bone
morphogenetic protein-10 suppresses the growth and aggressiveness
of prostate cancer cells through a Smad independent pathway. J
Urol. 181:2749–2759. 2009. View Article : Google Scholar : PubMed/NCBI
|
